The prediction comes back every few months: the Galaxy Watch line is about to get a United States green light for cuffless blood pressure estimation, some time between 2026 and 2027, and the watch on your wrist becomes the first to follow your pressure all day. It is a good story, and today it is only that. No regulatory filing for it is public, and Samsung's own position on the blood pressure feature it already ships points the other way.
If you are wearing a Galaxy Watch right now, the honest version is dull: none of this changes what your watch does this year. The useful part is why, and what would have to change first.
What is actually announced
Samsung switched blood pressure on for Galaxy Watch users in the United States on 31 March 2026, reaching the Galaxy Watch 4 and the models that came after it. Three details from Samsung's own description of the feature matter more than the headline did. The reading is taken on demand, not in the background. The watch has to be recalibrated against an upper-arm cuff every 28 days. And Samsung, in its statement to press about the rollout, described the feature as a wellness feature that is not intended for medical use and therefore not subject to FDA clearance. That is the opposite of a company walking a cuffless claim through a regulator.
Apple arrived through a different door. In September 2025 the FDA cleared its hypertension notifications, and the part that gets lost is that the cleared feature never produces a number. It looks at patterns across 30-day windows and tells you that signs of chronic high pressure are showing up. Apple's own follow-up instruction is to log readings with a cuff for seven days and bring them to a doctor.
The first cuffless monitor the FDA cleared for over-the-counter sale was not a smartwatch at all. In July 2025 Aktiia announced clearance for its G0 system, the band sold as Hilo, which the company presented as the first cuffless blood pressure monitor cleared for over-the-counter use in the country. That undercuts the most repeated part of the prediction: if a wrist-worn cuffless monitor is the milestone, a dedicated band got there first.
Measuring and estimating are different verbs
A cuff measures. It squeezes the artery shut and reads what happens as it releases, and the number falls out of that physical event. A watch never touches your artery. It shines light into the wrist, reads the shape and the timing of the pulse coming back, and runs that waveform through a model anchored to you on the day you calibrated it with a cuff. What comes out is an estimate of what the cuff would have said.
That is the whole reason the 28-day recalibration exists. The relationship between a pulse waveform and a pressure value is personal, and it moves, so the anchor goes stale on a schedule. Continuous, here, is not a better sensor. It means an estimate that holds without you re-anchoring it, through exercise, sleep, cold hands, a loose band and the years. That is a modelling and validation problem more than a hardware one, which is why it keeps slipping.
Announced, pending, guesswork
- Announced: Samsung's on-demand, cuff-calibrated reading in the United States since March 2026. Apple's hypertension notifications, cleared since September 2025. Aktiia's over-the-counter band.
- Pending: nothing public. Samsung has not announced a submission for a cuffless claim, and a clearance nobody has applied for has no timeline.
- Guesswork: the 2026 to 2027 window, the claim that a Galaxy Watch would be the first wrist device with continuous pressure, and every list of which models would get it.
One more piece of published record sits underneath all of it. On 16 September 2025 the FDA issued a safety communication telling people not to use unauthorized blood pressure devices, naming software features on smartwatches and smart rings specifically, and pointing readers to its own clearance database. A regulator that published that is not the regulator of the rumour.
What would have to be true before it matters to you
- An authorization covering a specific feature on a specific model. Brands do not get cleared; claims do.
- Recalibration gone, or stretched far enough that the cuff leaves the routine. Otherwise cuffless is a word, not a change.
- Validation across the people who would use it: ages, arm sizes, skin tones, arrhythmias. The estimate is a model, and a model has a population.
- Your country, separately. A United States clearance does nothing in Brazil or Argentina, where the local regulator decides on its own schedule.
- Your watch on the list. Health features tend to stay with newer hardware, and the model you own is the one the announcement will not mention.
What to do with the watch you already have
Treat what you have as a trend and a nudge, which is how the companies describe it when they are being careful. Keep the cuff. If a watch flags something, that is a reason to book an appointment, not to change a dose. And if you are choosing between models this year, blood pressure should not be the tiebreaker: nothing announced makes one wrist better than another here, and what Samsung actually changed in the Galaxy Watch 9 and the Ultra 2 is a firmer basis for choosing than a clearance nobody has filed.
The comparison that actually helps here is between the two approaches already on wrists: an on-demand estimate that needs a cuff every 28 days, and a cleared notification that never gives you a number. Reading what changed in the Apple Watch Series 12 and the Ultra 4 next to the Galaxy Watch 9 and the Ultra 2 is the cheapest way to see which of the two your own wrist is closer to, and how little of this depends on buying anything new.
Last updated September 21, 2026